KI
Therapeutic Areas
Acadia Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pimavanserin (NUPLAZID®) | Alzheimer's Disease Psychosis | Phase 3 |
| Trofinetide (DAYBUE®) | Rett Syndrome (EU Registration) | Registration |
| ACD-2019 | Undisclosed CNS Target | Discovery/Preclinical |
Leadership Team at Acadia Pharmaceuticals
SD
Stephen Davis
Chief Executive Officer
ER
Elena Ridloff, CFA
EVP, Chief Financial Officer
BT
Brendan Teehan, M.D.
EVP, Chief Medical Officer
AD
Austin D. Kim
EVP, General Counsel and Secretary
MS
Mark Schneyer
EVP, Head of Commercial
JM
Jonathan M. Poole
Board Member